Publications by authors named "Olga V Abramova"
Article Synopsis
- Inflammatory bowel diseases involve ongoing inflammation in the intestines and changes in gut microbiota, which can be influenced by outer membrane vesicles (OMVs) that contain polysaccharide A (PSA).
- The study used a mouse model of intestinal colitis induced by sodium dextran sulfate (DSS) and examined the effects of OMV treatment by assessing disease severity and gut tissue health through disease activity index (DAI) and histology.
- Results indicated that OMV treatment improved intestinal healing and altered microbiota composition, highlighting OMVs’ potential as both anti-inflammatory agents and facilitators of microbiota recovery.
Article Synopsis
- Inflammatory bowel diseases (IBD) are widespread but often show no symptoms early on, highlighting the need for effective, non-invasive diagnostic methods.
- This study proposes a technique to monitor IBD development by analyzing volatile organic compounds (VOCs) produced by gut microbiota using HS GC/MS during different inflammation stages in a rat model.
- Results showed significant changes in the metabolomic profile, particularly in short-chain fatty acids, during acute and remission phases of IBD, indicating potential biomarkers for early detection and monitoring of the disease.
The effectiveness of tumor therapy, especially immunotherapy and oncolytic virotherapy, critically depends on the activity of the host immune cells. However, various local and systemic mechanisms of immunosuppression operate in cancer patients. Tumor-associated immunosuppression involves deregulation of many components of immunity, including a decrease in the number of T lymphocytes (lymphopenia), an increase in the levels or ratios of circulating and tumor-infiltrating immunosuppressive subsets [e.
View Article and Find Full Text PDFThe need for paradigm shift: prognostic significance and implications of standard therapy-related systemic immunosuppression in glioblastoma for immunotherapy and oncolytic virotherapy.
Front Immunol
February 2024
Despite significant advances in our knowledge regarding the genetics and molecular biology of gliomas over the past two decades and hundreds of clinical trials, no effective therapeutic approach has been identified for adult patients with newly diagnosed glioblastoma, and overall survival remains dismal. Great hopes are now placed on combination immunotherapy. In clinical trials, immunotherapeutics are generally tested after standard therapy (radiation, temozolomide, and steroid dexamethasone) or concurrently with temozolomide and/or steroids.
View Article and Find Full Text PDFArticle Synopsis
- The LCGA-17 peptide is introduced as a new candidate for treating anxiety and depression, working through specific brain receptors and potentially enhancing GABA-A receptor activity.
- The study tested the effects of acute and chronic intranasal LCGA-17 on stress and anxiety in rats, using various behavioral tests that mimic symptoms of PTSD and depression.
- Results showed significant anxiolytic and antidepressant effects from LCGA-17, outperforming some existing treatments, and it also restored important neurotransmitter levels in the brain post-stress, suggesting its potential for rapid action in mental health treatment.
Introduction: Depression is one of the most common mental illnesses. Impaired neurogenesis is observed in depression. Biomarkers of impaired neurogenesis in depression can act as a useful objective and diagnostic and prognostic tool to determine the severity of depression.
View Article and Find Full Text PDF